RS51795B - 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidin-5-oni, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže - Google Patents

2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidin-5-oni, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže

Info

Publication number
RS51795B
RS51795B RS20110334A RSP20110334A RS51795B RS 51795 B RS51795 B RS 51795B RS 20110334 A RS20110334 A RS 20110334A RS P20110334 A RSP20110334 A RS P20110334A RS 51795 B RS51795 B RS 51795B
Authority
RS
Serbia
Prior art keywords
amino
pyrimidin
phenyl
methyl
fluoro
Prior art date
Application number
RS20110334A
Other languages
English (en)
Serbian (sr)
Inventor
Daniel Poon
Teresa Pick
Timothy D. Machajewski
Cynthia M. Shafer
Christopher Mcbride
William Antonios-Mccrea
Brandon M. Doughan
Barry H. Levine
Yi Xia
Maureen Mckenna
Michael X. Wang
Kris Mendenhall
Yasheen Zhou
Baoqing Gong
Dan Gu
John Dolan
John Tulinsky
Kristin Brinner
Zhenhai Gao
Paul A. Renhowe
Paul A. Barsanti
Hiaodong Lin
Abran Costales
Nathan Brammeier
Alice Rico
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of RS51795B publication Critical patent/RS51795B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
RS20110334A 2005-09-30 2006-09-28 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidin-5-oni, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže RS51795B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72279605P 2005-09-30 2005-09-30
US83688606P 2006-08-09 2006-08-09

Publications (1)

Publication Number Publication Date
RS51795B true RS51795B (sr) 2011-12-31

Family

ID=37661234

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20110334A RS51795B (sr) 2005-09-30 2006-09-28 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidin-5-oni, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže

Country Status (31)

Country Link
US (2) US7671059B2 (enExample)
EP (1) EP1928875B1 (enExample)
JP (2) JP5036002B2 (enExample)
KR (1) KR101311757B1 (enExample)
AR (1) AR058072A1 (enExample)
AT (1) ATE514694T1 (enExample)
AU (1) AU2006297124B2 (enExample)
BR (1) BRPI0616701A2 (enExample)
CA (1) CA2624253C (enExample)
CR (1) CR9846A (enExample)
CY (1) CY1112028T1 (enExample)
DK (1) DK1928875T3 (enExample)
EA (1) EA016152B1 (enExample)
EC (1) ECSP088324A (enExample)
GE (1) GEP20115231B (enExample)
HR (1) HRP20110655T1 (enExample)
IL (1) IL190446A0 (enExample)
JO (1) JO2783B1 (enExample)
MA (1) MA29885B1 (enExample)
ME (1) ME01952B (enExample)
MY (1) MY143604A (enExample)
NO (1) NO342258B1 (enExample)
NZ (1) NZ566914A (enExample)
PE (1) PE20070621A1 (enExample)
PL (1) PL1928875T3 (enExample)
PT (1) PT1928875E (enExample)
RS (1) RS51795B (enExample)
SM (1) SMAP200800029A (enExample)
TN (1) TNSN08143A1 (enExample)
TW (1) TWI373471B (enExample)
WO (1) WO2007041362A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CN101225083A (zh) * 2007-01-16 2008-07-23 北京摩力克科技有限公司 四氢喹唑啉酮类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
GB2449293A (en) * 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
BRPI0906598A2 (pt) * 2008-02-01 2015-07-07 Takeda Pharmaceutical Oxim derivattivos como inibidores hsp90
WO2010034670A2 (en) * 2008-09-26 2010-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Host cell kinases as targets for antiviral therapies against hcv infection
MA32933B1 (fr) * 2008-11-28 2012-01-02 Novartis Ag Combinaison d'inhibiteurs de hspo90 et d'herceptine
US20110230499A1 (en) * 2008-11-28 2011-09-22 Novartis Ag Hsp90 inhibitors for therapeutic treatment
PT2370076T (pt) * 2008-11-28 2017-03-31 Novartis Ag Combinações de inibidor hsp90
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2011053861A1 (en) 2009-10-29 2011-05-05 Genosco Kinase inhibitors
WO2012104823A2 (en) 2011-02-04 2012-08-09 Novartis Ag Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
KR20140078656A (ko) 2011-10-14 2014-06-25 노파르티스 아게 증식성 질환의 치료를 위한 hsp90 억제제와 조합된 2-카르복스아미드 시클로아미노 우레아 유도체
ITTO20111013A1 (it) 2011-11-03 2013-05-04 Dac Srl Composti farmaceutici
CN103664938A (zh) * 2012-09-12 2014-03-26 山东亨利医药科技有限责任公司 含有嘧啶并环的syk抑制剂
AU2013341271A1 (en) 2012-11-07 2015-05-14 Novartis Ag Combination therapy
US9677907B2 (en) * 2013-03-14 2017-06-13 Itron Inc Intelligent receptacle
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
PL3053578T3 (pl) * 2013-09-30 2021-06-14 Taiho Pharmaceutical Co., Ltd. Skojarzona terapia przeciwnowotworowa z zastosowaniem związku azabicyklicznego
CN106795154B (zh) * 2014-09-02 2019-07-05 皮埃尔法布雷医药公司 用于治疗癌症的异喹啉酮衍生物
KR20160035411A (ko) * 2014-09-23 2016-03-31 주식회사 오스코텍 LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물
KR101653560B1 (ko) * 2016-02-02 2016-09-12 한국화학연구원 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물
RU2629599C1 (ru) * 2016-09-28 2017-08-30 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ химиолучевого лечения опухолей прямой кишки и анального канала
US11542299B2 (en) 2017-06-09 2023-01-03 Chugai Seiyaku Kabushiki Kaisha Method for synthesizing peptide containing N-substituted amino acid
US20230295108A1 (en) * 2020-06-26 2023-09-21 Nihon Nohyaku Co., Ltd. Aryltetrahydropyridine derivative or salt thereof, insecticidal agent containing the compound, and method of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6165873A (ja) * 1984-09-07 1986-04-04 Mitsui Petrochem Ind Ltd ２−ピペラジノピリミジン誘導体
CA1307786C (en) 1984-12-14 1992-09-22 Keiichi Yokoyama Quinazoline derivatives and antihypertensive preparations containing same as effective components
IL85347A0 (en) * 1987-02-11 1988-07-31 May & Baker Ltd Cyclic diones
ATE305303T1 (de) * 2001-02-12 2005-10-15 Hoffmann La Roche 6-substituierte pyridopyrimidine
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
CA2584485C (en) 2004-10-20 2013-12-31 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
WO2006074293A2 (en) * 2005-01-07 2006-07-13 President And Fellows Of Harvard College Bicyclic dihydropyrimidines as eg5 inhibitors
JP2008536867A (ja) * 2005-04-14 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 増殖疾患を処置する際に有用なｈｓｐ９０インヒビターとしての２−アミノ−キナゾリン−５−オン

Also Published As

Publication number Publication date
IL190446A0 (en) 2008-11-03
KR20080057318A (ko) 2008-06-24
US20070123546A1 (en) 2007-05-31
TNSN08143A1 (en) 2009-07-14
US7671059B2 (en) 2010-03-02
HK1118823A1 (en) 2009-02-20
CA2624253A1 (en) 2007-04-12
MY143604A (en) 2011-06-15
JP2009510108A (ja) 2009-03-12
GEP20115231B (en) 2011-06-10
JP5036002B2 (ja) 2012-09-26
NZ566914A (en) 2011-09-30
PL1928875T3 (pl) 2011-11-30
HRP20110655T1 (hr) 2011-10-31
AU2006297124B2 (en) 2011-12-08
CA2624253C (en) 2015-06-16
SMP200800029B (it) 2008-05-07
KR101311757B1 (ko) 2013-09-26
WO2007041362A1 (en) 2007-04-12
MA29885B1 (fr) 2008-10-03
US20100004237A1 (en) 2010-01-07
ME01952B (en) 2011-12-31
ECSP088324A (es) 2008-04-28
BRPI0616701A2 (pt) 2011-06-28
TWI373471B (en) 2012-10-01
EA016152B1 (ru) 2012-02-28
DK1928875T3 (da) 2011-10-03
CY1112028T1 (el) 2015-11-04
EP1928875B1 (en) 2011-06-29
NO20082069L (no) 2008-06-09
EA200800992A1 (ru) 2008-10-30
JO2783B1 (en) 2014-03-15
PE20070621A1 (es) 2007-09-06
SMAP200800029A (it) 2008-05-07
NO342258B1 (no) 2018-04-30
JP2012158611A (ja) 2012-08-23
TW200728304A (en) 2007-08-01
EP1928875A1 (en) 2008-06-11
PT1928875E (pt) 2011-09-06
AU2006297124A1 (en) 2007-04-12
ATE514694T1 (de) 2011-07-15
AR058072A1 (es) 2008-01-23
CR9846A (es) 2008-08-01

Similar Documents

Publication Publication Date Title
RS51795B (sr) 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidin-5-oni, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže
JP5406039B2 (ja) タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
CA3042960C (en) Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof
ES2809974T3 (es) Compuestos de indol carboxamida útiles como inhibidores de cinasas
CN116332948A (zh) 一种含氮四环化合物及其制备方法和药用用途
WO2003063874A1 (en) Condensed heterocyclic compounds
JP2008536867A (ja) 増殖疾患を処置する際に有用なｈｓｐ９０インヒビターとしての２−アミノ−キナゾリン−５−オン
JP2022545930A (ja) Ｆｇｆｒ阻害剤とするピラゾール類誘導体及びその調製方法
CN104447765A (zh) 三环化合物及其药物组合物和应用
KR20060092297A (ko) 유도성 일산화질소 합성효소 억제제인 이미다조피리딘유도체
CN101287734B (zh) 2-氨基-7,8-二氢-6H-吡啶并[4,3-d]嘧啶-5-酮
CN115785074A (zh) Parp7抑制剂及其用途
ES2369707T3 (es) 2-amino-7,8-dihidro-6h-pirido(4,3-d)pirimidin-5-onas, procedimiento para su preparación y composiciones farmacéuticas que contienen las mismas.
HK1123801A (zh) 2-氨基-7，8-二氢-6h-吡啶并[4，3-d]嘧啶-5-酮
HK1118823B (en) 2-amino-7,8-dihydro-6h-pyrido(4,3-d)pyrimidin-5-ones, process for their preparation and pharmaceutical compositions containing the same
HK1122275A (en) 2-amino-quinazolin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
NZ787350A (en) Heterocyclic compounds as ret kinase inhibitors